Phase I and Pharmacokinetic Study of Daily Oral AZD2171, an Inhibitor of Vascular Endothelial Growth Factor Tyrosine Kinases, in Combination With Carboplatin and Paclitaxel in Patients With Advanced Non–Small-Cell Lung Cancer: The National Cancer Institute of Canada Clinical Trials GroupScott A. Laurie, Lesley Seymour, Isabelle Gauthier et al.|Journal of Clinical Oncology|2008Cited by 120
Plasma Transforming Growth Factor α and Amphiregulin Protein Levels in NCIC Clinical Trials Group BR.21Christina Addison, Penelope A. Bradbury, Frances A. Shepherd et al.|Journal of Clinical Oncology|2010Cited by 55
Correlation of Lactate Dehydrogenase Isoenzyme Profile With Outcome in Patients With Advanced Colorectal Cancer Treated With Chemotherapy and Bevacizumab or Cediranib: Retrospective Analysis of the HORIZON I StudyJair Bar, Glenwood D. Goss, Stuart Spencer et al.|Clinical Colorectal Cancer|2013Cited by 29
Final clinical and pharmacokinetic (PK) results from a phase 1 study of the novel N-cadherin (N-cad) antagonist, Exherin (ADH-1), in patients with refractory solid tumors stratified according to N-cad expressionDavid J. Stewart, W. P. Peters, Derek J. Jonker et al.|Journal of Clinical Oncology|2006Cited by 14
Angiotensin-Converting Enzyme and Aldosterone Serum Levels as Prognostic and Predictive Biomarkers for Cediranib in NCIC Clinical Trials Group Study BR.24Jair Bar, Penelope A. Bradbury, Frances A. Shepherd et al.|Clinical Lung Cancer|2015Cited by 7